Publications 2020

Brustugun OT (2020)
Cancer treatment and covid-19
Tidsskr. Nor. Laegeforen., 140 (7), 622

Brustugun OT (2020)
Kreftbehandling og covid-19
Tidsskr Nor Laegeforen, 140 (7)
DOI 10.4045/tidsskr.20.0280, PubMed 32378865

Brustugun OT, Sorhaug S, Gronberg BH, Aanerud M, Al-Zubayidy MMZ, Fjellbirkeland L, Helland A, Berg J, Andreassen B, Paulsen EE, Haram PM, Ashraf H, Wahl SGF (2020)
Lung cancer: Improved prognosis presents capacity challenges
Tidsskr. Nor. Laegeforen., 140 (5), 432-434

Brustugun OT, Sørhaug S, Grønberg BH, Aanerud M, Al-Zubayidy MMZ, Fjellbirkeland L, Helland Å, Berg J, Andreassen B, Paulsen EE, Haram PM, Ashraf H, Wahl SGF (2020)
Lungekreft: Forbedret prognose gir kapasitetsutfordringer
Tidsskr Nor Laegeforen, 140 (5)
DOI 10.4045/tidsskr.20.0014, PubMed 32238965

Eide IJZ, Helland Å, Ekman S, Mellemgaard A, Hansen KH, Cicenas S, Koivunen J, Grønberg BH, Brustugun OT (2020)
Osimertinib in T790M-positive and -negative patients with EGFR-mutated advanced non-small cell lung cancer (the TREM-study)
Lung Cancer, 143, 27-35
DOI 10.1016/j.lungcan.2020.03.009, PubMed 32200138

Frafjord A, Skarshaug R, Hammarström C, Stankovic B, Dorg LT, Aamodt H, Woldbaek PR, Helland Å, Brustugun OT, Øynebråten I, Corthay A (2020)
Antibody combinations for optimized staining of macrophages in human lung tumours
Scand J Immunol, 92 (1), e12889
DOI 10.1111/sji.12889, PubMed 32299134

Garon EB, Scagliotti GV, Gautschi O, Reck M, Thomas M, Iglesias Docampo L, Kalofonos H, Kim JH, Gans S, Brustugun OT, Orlov SV, Cuyun Carter G, Zimmermann AH, Oton AB, Alexandris E, Lee P, Wolff K, Stefaniak VJ, Socinski MA, Pérol M (2020)
Exploratory analysis of front-line therapies in REVEL: a randomised phase 3 study of ramucirumab plus docetaxel versus docetaxel for the treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy
ESMO Open, 5 (1)
DOI 10.1136/esmoopen-2019-000567, PubMed 31958290

Halvorsen TO, Stokke K, Killingberg KT, Raj SX, Sørhaug S, Brustugun OT, Fløtten Ø, Helbekkmo N, Hornslien K, Madebo T, Fluge S, Grønberg BH (2020)
Randomized phase III trial comparing switch-maintenance pemetrexed with observation followed by pemetrexed at progression in advanced NSCLC
Acta Oncol, 59 (9), 1051-1057
DOI 10.1080/0284186X.2020.1778179, PubMed 32543258

Haakensen VD, Khadse A, Sandhu V, Halvorsen AR, Solberg SK, Jørgensen LH, Brustugun OT, Kure EH, Helland Å (2020)
Molecular characterisation of TP53 mutated squamous cell carcinomas of the lung to identify putative targets for therapy
Int J Cancer
DOI 10.1002/ijc.33121, PubMed 32468587

Laerum D, Brustugun OT, Gallefoss F, Falk R, Strand TE, Fjellbirkeland L (2020)
Reduced delays in diagnostic pathways for non-small cell lung cancer after local and National initiatives
Cancer Treat Res Commun, 23, 100168 (in press)
DOI 10.1016/j.ctarc.2020.100168, PubMed 32028190

Nilssen Y, Brustugun OT, Eriksen MT, Haug ES, Naume B, Møller B (2020)
Patient and tumour characteristics associated with inclusion in Cancer patient pathways in Norway in 2015-2016
BMC Cancer, 20 (1), 488
DOI 10.1186/s12885-020-06979-y, PubMed 32473650

Stankovic B, Aamodt H, Bjørhovde HAK, Müller E, Hammarström C, Brustugun OT, Helland Å, Øynebråten I, Corthay A (2020)
The immune microenvironment in typical carcinoid lung tumour, a brief report of four cases
Scand J Immunol, 92 (2), e12893
DOI 10.1111/sji.12893, PubMed 32433774

Publications 2019

Alcala N, Leblay N, Gabriel AAG, Mangiante L, Hervas D, Giffon T, Sertier AS, Ferrari A, Derks J, Ghantous A, Delhomme TM, Chabrier A, Cuenin C, Abedi-Ardekani B, Boland A, Olaso R, Meyer V, Altmuller J, Le Calvez-Kelm F, Durand G, Voegele C, Boyault S, Moonen L, Lemaitre N, Lorimier P et al. (2019)
Integrative and comparative genomic analyses identify clinically relevant pulmonary carcinoid groups and unveil the supra-carcinoids
Nat Commun, 10 (1), 3407
DOI 10.1038/s41467-019-11276-9, PubMed 31431620

Brustugun OT (2019)
A NOTCH added to metabolomics
Br J Cancer, 121 (1), 3-4
DOI 10.1038/s41416-019-0463-0, PubMed 31114016

Halvorsen AR, Ragle Aure M, Õjlert ÅK, Brustugun OT, Solberg S, Nebdal D, Helland Å (2019)
Identification of microRNAs involved in pathways which characterize the expression subtypes of NSCLC
Mol Oncol, 13 (12), 2604-2615
DOI 10.1002/1878-0261.12571, PubMed 31505091

Menon U, Vedsted P, Zalounina Falborg A, Jensen H, Harrison S, Reguilon I, Barisic A, Bergin RJ, Brewster DH, Butler J, Brustugun OT, Bucher O, Cairnduff V, Gavin A, Grunfeld E, Harland E, Kalsi J, Knudsen AK, Lambe M, Law RJ, Lin Y, Malmberg M, Turner D, Neal RD, White V et al. (2019)
Time intervals and routes to diagnosis for lung cancer in 10 jurisdictions: cross-sectional study findings from the International Cancer Benchmarking Partnership (ICBP)
BMJ Open, 9 (11), e025895
DOI 10.1136/bmjopen-2018-025895, PubMed 31776134

Nilssen Y, Brustugun OT, Tandberg Eriksen M, Gulbrandsen J, Skaaheim Haug E, Naume B, Møller B (2019)
Decreasing waiting time for treatment before and during implementation of cancer patient pathways in Norway
Cancer Epidemiol, 61, 59-69
DOI 10.1016/j.canep.2019.05.004, PubMed 31153048

Solberg S, Nilssen Y, Brustugun OT, Grimsrud TK, Haram PM, Helbekkmo N, Helland Å, Hjelde HH, Jakobsen B, Møller B, Petersen M, Strand TE, Wahl SGF, Aanerud M, Fjellbirkeland L (2019)
Increase in curative treatment and survival of lung cancer in Norway 2001-2016
Eur J Epidemiol, 34 (10), 951-955
DOI 10.1007/s10654-019-00536-z, PubMed 31313073

Stankovic B, Bjørhovde HAK, Skarshaug R, Aamodt H, Frafjord A, Müller E, Hammarström C, Beraki K, Bækkevold ES, Woldbæk PR, Helland Å, Brustugun OT, Øynebråten I, Corthay A (2019)
Immune Cell Composition in Human Non-small Cell Lung Cancer
Front Immunol, 9, 3101
DOI 10.3389/fimmu.2018.03101, PubMed 30774636

Öjlert ÅK, Halvorsen AR, Nebdal D, Lund-Iversen M, Solberg S, Brustugun OT, Lingjaerde OC, Helland Å (2019)
The immune microenvironment in non-small cell lung cancer is predictive of prognosis after surgery
Mol Oncol, 13 (5), 1166-1179
DOI 10.1002/1878-0261.12475, PubMed 30854794

Publications 2018

Berg J, Halvorsen AR, Bengtson MB, Taskén KA, Mælandsmo GM, Yndestad A, Halvorsen B, Brustugun OT, Aukrust P, Ueland T, Helland Å (2018)
Levels and prognostic impact of circulating markers of inflammation, endothelial activation and extracellular matrix remodelling in patients with lung cancer and chronic obstructive pulmonary disease
BMC Cancer, 18 (1), 739
DOI 10.1186/s12885-018-4659-0, PubMed 30005623

Brustugun OT, Grønberg BH, Fjellbirkeland L, Helbekkmo N, Aanerud M, Grimsrud TK, Helland Å, Møller B, Nilssen Y, Strand TE, Solberg SK (2018)
Substantial nation-wide improvement in lung cancer relative survival in Norway from 2000 to 2016
Lung Cancer, 122, 138-145
DOI 10.1016/j.lungcan.2018.06.003, PubMed 30032822

Bugge AS, Lund MB, Valberg M, Brustugun OT, Solberg S, Kongerud J (2018)
Cause-specific death after surgical resection for early-stage non-small-cell lung cancer
Eur J Cardiothorac Surg, 53 (1), 221-227
DOI 10.1093/ejcts/ezx274, PubMed 28950311

Eide HA, Knudtsen IS, Sandhu V, Løndalen AM, Halvorsen AR, Abravan A, Kure EH, Bogsrud TV, Brustugun OT, Kyte JA, Malinen E, Helland Å (2018)
Serum cytokine profiles and metabolic tumor burden in patients with non-small cell lung cancer undergoing palliative thoracic radiation therapy
Adv Radiat Oncol, 3 (2), 130-138
DOI 10.1016/j.adro.2017.12.007, PubMed 29904737

George J, Walter V, Peifer M, Alexandrov LB, Seidel D, Leenders F, Maas L, Müller C, Dahmen I, Delhomme TM, Ardin M, Leblay N, Byrnes G, Sun R, De Reynies A, McLeer-Florin A, Bosco G, Malchers F, Menon R, Altmüller J, Becker C, Nürnberg P, Achter V, Lang U, Schneider PM et al. (2018)
Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors
Nat Commun, 9 (1), 1048
DOI 10.1038/s41467-018-03099-x, PubMed 29535388

Halvorsen AR, Sandhu V, Sprauten M, Flote VG, Kure EH, Brustugun OT, Helland Å (2018)
Circulating microRNAs associated with prolonged overall survival in lung cancer patients treated with nivolumab
Acta Oncol, 57 (9), 1225-1231
DOI 10.1080/0284186X.2018.1465585, PubMed 29683761

Lund-Iversen M, Scott H, Strøm EH, Theiss N, Brustugun OT, Grønberg BH (2018)
Expression of Estrogen Receptor-α and Survival in Advanced-stage Non-small Cell Lung Cancer
Anticancer Res, 38 (4), 2261-2269
DOI 10.21873/anticanres.12470, PubMed 29599348

Valan CD, Slagsvold JE, Halvorsen TO, Herje M, Bremnes RM, Brunsvig PF, Brustugun OT, Fløtten Ø, Levin N, Sundstrøm SH, Grønberg BH (2018)
Survival in Limited Disease Small Cell Lung Cancer According to N3 Lymph Node Involvement
Anticancer Res, 38 (2), 871-876
DOI 10.21873/anticanres.12296, PubMed 29374714

Publications 2017

Helland Å, Brustugun OT, Nakken S, Halvorsen AR, Dønnem T, Bremnes R, Busund LT, Sun J, Lorenz S, Solberg SK, Jørgensen LH, Vodak D, Myklebost O, Hovig E, Meza-Zepeda LA (2017)
High number of kinome-mutations in non-small cell lung cancer is associated with reduced immune response and poor relapse-free survival
Int J Cancer, 141 (1), 184-190
DOI 10.1002/ijc.30726, PubMed 28387924

McGowan M, Kleinberg L, Halvorsen AR, Helland Å, Brustugun OT (2017)
NSCLC depend upon YAP expression and nuclear localization after acquiring resistance to EGFR inhibitors
Genes Cancer, 8 (3-4), 497-504
DOI 10.18632/genesandcancer.136, PubMed 28680534

Meyer M, Vliegenthart R, Henzler T, Buergy D, Giordano FA, Kostrzewa M, Rathmann N, Brustugun OT, Crino L, Dingemans AC, Dusmet M, Fennell D, Grunenwald D, Huber RM, Moniuszko M, Mornex F, Papotti M, Pilz L, Senan S, Syrigos K, Pérol M, Gray JE, Schabel C, van Meerbeeck JP, van Zandwijk N et al. (2017)
Management of Progressive Pulmonary Nodules Found during and outside of CT Lung Cancer Screening Studies
J Thorac Oncol, 12 (12), 1755-1765
DOI 10.1016/j.jtho.2017.09.1956, PubMed 28962947

Pedersen JH, Sørensen JB, Saghir Z, Fløtten Ø, Brustugun OT, Ashraf H, Strand TE, Friesland S, Koyi H, Ek L, Nyrén S, Bergman P, Jekunen A, Nieminen EM, Gudbjartsson T (2017)
Implementation of lung cancer CT screening in the Nordic countries
Acta Oncol, 56 (10), 1249-1257
DOI 10.1080/0284186X.2017.1329592, PubMed 28571524

Publications 2016

Brustugun OT, Sprauten M, Helland Å (2016)
Real-world data on nivolumab treatment of non-small cell lung cancer
Acta Oncol, 56 (3), 438-440
DOI 10.1080/0284186X.2016.1253865, PubMed 27892773

Eide HA, Halvorsen AR, Bjaanæs MM, Piri H, Holm R, Solberg S, Jørgensen L, Brustugun OT, Kiserud CE, Helland Å (2016)
The MYCN-HMGA2-CDKN2A pathway in non-small cell lung carcinoma--differences in histological subtypes
BMC Cancer, 16, 71
DOI 10.1186/s12885-016-2104-9, PubMed 26858029

Eide HA, Halvorsen AR, Sandhu V, Fåne A, Berg J, Haakensen VD, Kure EH, Brustugun OT, Kiserud CE, Kyte JA, Helland Å (2016)
Non-small cell lung cancer is characterised by a distinct inflammatory signature in serum compared with chronic obstructive pulmonary disease
Clin Transl Immunology, 5 (11), e109
DOI 10.1038/cti.2016.65, PubMed 27990285

Halvorsen AR, Bjaanæs M, LeBlanc M, Holm AM, Bolstad N, Rubio L, Peñalver JC, Cervera J, Mojarrieta JC, López-Guerrero JA, Brustugun OT, Helland Å (2016)
A unique set of 6 circulating microRNAs for early detection of non-small cell lung cancer
Oncotarget, 7 (24), 37250-37259
DOI 10.18632/oncotarget.9363, PubMed 27191990

Halvorsen AR, Silwal-Pandit L, Meza-Zepeda LA, Vodak D, Vu P, Sagerup C, Hovig E, Myklebost O, Børresen-Dale AL, Brustugun OT, Helland Å (2016)
TP53 Mutation Spectrum in Smokers and Never Smoking Lung Cancer Patients
Front Genet, 7, 85
DOI 10.3389/fgene.2016.00085, PubMed 27242894

Halvorsen TO, Herje M, Levin N, Bremnes RM, Brustugun OT, Fløtten Ø, Kaasa S, Sundstrøm S, Grønberg BH (2016)
Tumour size reduction after the first chemotherapy-course and outcomes of chemoradiotherapy in limited disease small-cell lung cancer
Lung Cancer, 102, 9-14
DOI 10.1016/j.lungcan.2016.10.003, PubMed 27987595

Halvorsen TO, Sundstrøm S, Fløtten Ø, Brustugun OT, Brunsvig P, Aasebø U, Bremnes RM, Kaasa S, Grønberg BH (2016)
Comorbidity and outcomes of concurrent chemo- and radiotherapy in limited disease small cell lung cancer
Acta Oncol, 55 (11), 1349-1354
DOI 10.1080/0284186X.2016.1201216, PubMed 27549509

Joly-Battaglini A, Hammarström C, Stankovic B, Aamodt H, Stjärne J, Brustugun OT, Helland Å, Øynebråten I, Corthay A (2016)
Rituximab efficiently depletes B cells in lung tumors and normal lung tissue
F1000Res, 5, 38
DOI 10.12688/f1000research.7599.1, PubMed 27081474

Manegold C, Dingemans AC, Gray JE, Nakagawa K, Nicolson M, Peters S, Reck M, Wu YL, Brustugun OT, Crinò L, Felip E, Fennell D, Garrido P, Huber RM, Marabelle A, Moniuszko M, Mornex F, Novello S, Papotti M, Pérol M, Smit EF, Syrigos K, van Meerbeeck JP, van Zandwijk N, Yang JC et al. (2016)
The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC
J Thorac Oncol, 12 (2), 194-207
DOI 10.1016/j.jtho.2016.10.003, PubMed 27729297

McGowan M, Hoven AS, Lund-Iversen M, Solberg S, Helland Å, Hirsch FR, Brustugun OT (2016)
PIK3CA mutations as prognostic factor in squamous cell lung carcinoma
Lung Cancer, 103, 52-57
DOI 10.1016/j.lungcan.2016.11.018, PubMed 28024696

Nyman J, Hallqvist A, Lund JÅ, Brustugun OT, Bergman B, Bergström P, Friesland S, Lewensohn R, Holmberg E, Lax I (2016)
SPACE - A randomized study of SBRT vs conventional fractionated radiotherapy in medically inoperable stage I NSCLC
Radiother Oncol, 121 (1), 1-8
DOI 10.1016/j.radonc.2016.08.015, PubMed 27600155

Rud AK, Boye K, Fodstad Ø, Juell S, Jørgensen LH, Solberg S, Helland Å, Brustugun OT, Mælandsmo GM (2016)
Detection of disseminated tumor cells in lymph nodes from patients with early stage non-small cell lung cancer
Diagn Pathol, 11 (1), 50
DOI 10.1186/s13000-016-0504-4, PubMed 27316334

Weischenfeldt J, Dubash T, Drainas AP, Mardin BR, Chen Y, Stütz AM, Waszak SM, Bosco G, Halvorsen AR, Raeder B, Efthymiopoulos T, Erkek S, Siegl C, Brenner H, Brustugun OT, Dieter SM, Northcott PA, Petersen I, Pfister SM, Schneider M, Solberg SK, Thunissen E, Weichert W, Zichner T, Thomas R et al. (2016)
Pan-cancer analysis of somatic copy-number alterations implicates IRS4 and IGF2 in enhancer hijacking
Nat Genet, 49 (1), 65-74
DOI 10.1038/ng.3722, PubMed 27869826

Publications 2015

Berg AS, Løndalen A, Brustugun OT (2015)
[Typical growth pattern in malignant pleural mesothelioma]
Tidsskr Nor Laegeforen, 135 (11), 1050
DOI 10.4045/tidsskr.14.0480, PubMed 26080781

Berg J, Fjellbirkeland L, Suhrke P, Jebsen P, Lund-Iversen M, Kleinberg L, Helgeland L, Brustugun OT, Helland Å (2015)
EGFR mutation testing of lung cancer patients - Experiences from Vestfold Hospital Trust
Acta Oncol, 55 (2), 149-55
DOI 10.3109/0284186X.2015.1062537, PubMed 26313507

Bjaanæs MM, Fleischer T, Halvorsen AR, Daunay A, Busato F, Solberg S, Jørgensen L, Kure E, Edvardsen H, Børresen-Dale AL, Brustugun OT, Tost J, Kristensen V, Helland Å (2015)
Genome-wide DNA methylation analyses in lung adenocarcinomas: Association with EGFR, KRAS and TP53 mutation status, gene expression and prognosis
Mol Oncol, 10 (2), 330-43
DOI 10.1016/j.molonc.2015.10.021, PubMed 26601720

Brustugun OT (2015)
[Re: In momentous development?]
Tidsskr Nor Laegeforen, 135 (5), 413-4
DOI 10.4045/tidsskr.15.0208, PubMed 25761018

Donnem T, Hald SM, Paulsen EE, Richardsen E, Al-Saad S, Kilvaer TK, Brustugun OT, Helland A, Lund-Iversen M, Poehl M, Olsen KE, Ditzel HJ, Hansen O, Al-Shibli K, Kiselev Y, Sandanger TM, Andersen S, Pezzella F, Bremnes RM, Busund LT (2015)
Stromal CD8+ T-cell Density—A Promising Supplement to TNM Staging in Non-Small Cell Lung Cancer
Clin Cancer Res, 21 (11), 2635-43
DOI 10.1158/1078-0432.CCR-14-1905, PubMed 25680376

Donnem T, Kilvaer TK, Andersen S, Richardsen E, Paulsen EE, Hald SM, Al-Saad S, Brustugun OT, Helland A, Lund-Iversen M, Solberg S, Gronberg BH, Wahl SG, Helgeland L, Fløtten O, Pohl M, Al-Shibli K, Sandanger TM, Pezzella F, Busund LT, Bremnes RM (2015)
Strategies for clinical implementation of TNM-Immunoscore in resected nonsmall-cell lung cancer
Ann Oncol, 27 (2), 225-32
DOI 10.1093/annonc/mdv560, PubMed 26578726

Fernandez-Cuesta L, Sun R, Menon R, George J, Lorenz S, Meza-Zepeda LA, Peifer M, Plenker D, Heuckmann JM, Leenders F, Zander T, Dahmen I, Koker M, Schöttle J, Ullrich RT, Altmüller J, Becker C, Nürnberg P, Seidel H, Böhm D, Göke F, Ansén S, Russell PA, Wright GM, Wainer Z et al. (2015)
Identification of novel fusion genes in lung cancer using breakpoint assembly of transcriptome sequencing data
Genome Biol, 16, 7
DOI 10.1186/s13059-014-0558-0, PubMed 25650807

George J, Lim JS, Jang SJ, Cun Y, Ozretić L, Kong G, Leenders F, Lu X, Fernández-Cuesta L, Bosco G, Müller C, Dahmen I, Jahchan NS, Park KS, Yang D, Karnezis AN, Vaka D, Torres A, Wang MS, Korbel JO, Menon R, Chun SM, Kim D, Wilkerson M, Hayes N et al. (2015)
Comprehensive genomic profiles of small cell lung cancer
Nature, 524 (7563), 47-53
DOI 10.1038/nature14664, PubMed 26168399

Grønberg BH, Halvorsen TO, Fløtten Ø, Brustugun OT, Brunsvig PF, Aasebø U, Bremnes RM, Tollåli T, Hornslien K, Aksnessæther BY, Liaaen ED, Sundstrøm S, Norwegian Lung Cancer Study Group (2015)
Randomized phase II trial comparing twice daily hyperfractionated with once daily hypofractionated thoracic radiotherapy in limited disease small cell lung cancer
Acta Oncol, 55 (5), 591-7
DOI 10.3109/0284186X.2015.1092584, PubMed 26494411

Lund-Iversen M, Grøholt KK, Helland Å, Borgen E, Brustugun OT (2015)
NUT expression in primary lung tumours
Diagn Pathol, 10, 156
DOI 10.1186/s13000-015-0395-9, PubMed 26341600

Nilssen Y, Strand TE, Fjellbirkeland L, Bartnes K, Brustugun OT, O'Connell DL, Yu XQ, Møller B (2015)
Lung cancer treatment is influenced by income, education, age and place of residence in a country with universal health coverage
Int J Cancer, 138 (6), 1350-60
DOI 10.1002/ijc.29875, PubMed 26421593

Publications 2014

Bjaanaes MM, Halvorsen AR, Solberg S, Jørgensen L, Dragani TA, Galvan A, Colombo F, Anderlini M, Pastorino U, Kure E, Børresen-Dale AL, Brustugun OT, Helland A (2014)
Unique microRNA-profiles in EGFR-mutated lung adenocarcinomas
Int J Cancer, 135 (8), 1812-21
DOI 10.1002/ijc.28828, PubMed 24599520

Brustugun OT (2014)
Hypoxia as a cause of treatment failure in non-small cell carcinoma of the lung
Semin Radiat Oncol, 25 (2), 87-92
DOI 10.1016/j.semradonc.2014.11.006, PubMed 25771412

Brustugun OT, Helland Å, Julsrud L (2014)
[Time counts!]
Tidsskr Nor Laegeforen, 134 (9), 915
DOI 10.4045/tidsskr.14.0057, PubMed 24828708

Brustugun OT, Khattak AM, Trømborg AK, Beigi M, Beiske K, Lund-Iversen M, Helland Å (2014)
BRAF-mutations in non-small cell lung cancer
Lung Cancer, 84 (1), 36-8
DOI 10.1016/j.lungcan.2014.01.023, PubMed 24552757

Brustugun OT, Møller B, Helland A (2014)
Years of life lost as a measure of cancer burden on a national level
Br J Cancer, 111 (5), 1014-20
DOI 10.1038/bjc.2014.364, PubMed 24983370

Fernandez-Cuesta L, Peifer M, Lu X, Sun R, Ozretić L, Seidal D, Zander T, Leenders F, George J, Müller C, Dahmen I, Pinther B, Bosco G, Konrad K, Altmüller J, Nürnberg P, Achter V, Lang U, Schneider PM, Bogus M, Soltermann A, Brustugun OT, Helland Å, Solberg S, Lund-Iversen M et al. (2014)
Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids
Nat Commun, 5, 3518
DOI 10.1038/ncomms4518, PubMed 24670920

Mynarek G, Aaløkken TM, Martinsen AC, Brustugun OT (2014)
[Re: Limited malignancy screening of patients with idiopathic venous thromboembolism]
Tidsskr Nor Laegeforen, 134 (8), 814-5
DOI 10.4045/tidsskr.14.0468, PubMed 24780975

Sagerup CM, Nymoen DA, Halvorsen AR, Lund-Iversen M, Helland A, Brustugun OT (2014)
Human papilloma virus detection and typing in 334 lung cancer patients
Acta Oncol, 53 (7), 952-7
DOI 10.3109/0284186X.2013.879608, PubMed 24446743

Publications 2013

Brustugun OT, Helland Å (2013)
Rapid reduction in the incidence of cancer of unknown primary. A population-based study
Acta Oncol, 53 (1), 134-7
DOI 10.3109/0284186X.2013.783230, PubMed 23550957

Grønberg BH, Lund-Iversen M, Strøm EH, Brustugun OT, Scott H (2013)
Associations between TS, TTF-1, FR-α, FPGS, and overall survival in patients with advanced non-small-cell lung cancer receiving pemetrexed plus carboplatin or gemcitabine plus carboplatin as first-line chemotherapy
J Thorac Oncol, 8 (10), 1255-64
DOI 10.1097/JTO.0b013e3182a406a3, PubMed 24457236

Nordgård O, Singh G, Solberg S, Jørgensen L, Halvorsen AR, Smaaland R, Brustugun OT, Helland Å (2013)
Novel molecular tumor cell markers in regional lymph nodes and blood samples from patients undergoing surgery for non-small cell lung cancer
PLoS One, 8 (5), e62153
DOI 10.1371/journal.pone.0062153, PubMed 23671585

Rud AK, Borgen E, Mælandsmo GM, Flatmark K, Le H, Josefsen D, Solvoll I, Schirmer CB, Helland Å, Jørgensen L, Brustugun OT, Fodstad Ø, Boye K (2013)
Clinical significance of disseminated tumour cells in non-small cell lung cancer
Br J Cancer, 109 (5), 1264-70
DOI 10.1038/bjc.2013.450, PubMed 23942067

Rud AK, Boye K, Oijordsbakken M, Lund-Iversen M, Halvorsen AR, Solberg SK, Berge G, Helland A, Brustugun OT, Mælandsmo GM (2013)
Osteopontin is a prognostic biomarker in non-small cell lung cancer
BMC Cancer, 13, 540
DOI 10.1186/1471-2407-13-540, PubMed 24215488

Publications 2012

Brustugun OT, Helland Å, Fjellbirkeland L, Kleinberg L, Ariansen S, Jebsen P, Scott H, Dønnem T, Bremnes R, Berg T, Grønberg BH, Dai HY, Wahl SG, Mangseth K, Helgeland L (2012)
[Mutation testing for non-small-cell lung cancer]
Tidsskr Nor Laegeforen, 132 (8), 952-5
DOI 10.4045/tidsskr.11.1017, PubMed 22562326

Helland Å, Solberg S, Brustugun OT (2012)
Incidence and survival of malignant pleural mesothelioma in norway: a population-based study of 1686 cases
J Thorac Oncol, 7 (12), 1858-1861
DOI 10.1097/JTO.0b013e318275b346, PubMed 23154557

Lund-Iversen M, Kleinberg L, Fjellbirkeland L, Helland Å, Brustugun OT (2012)
Clinicopathological characteristics of 11 NSCLC patients with EGFR-exon 20 mutations
J Thorac Oncol, 7 (9), 1471-3
DOI 10.1097/JTO.0b013e3182614a9d, PubMed 22895145

Nordlund MS, Stieber P, Brustugun OT, Warren DJ, Paus E (2012)
Characteristics and clinical validity of two immunoassays for ProGRP
Tumour Biol, 33 (4), 1105-13
DOI 10.1007/s13277-012-0351-1, PubMed 22399443

Peifer M, Fernández-Cuesta L, Sos ML, George J, Seidel D, Kasper LH, Plenker D, Leenders F, Sun R, Zander T, Menon R, Koker M, Dahmen I, Müller C, Di Cerbo V, Schildhaus HU, Altmüller J, Baessmann I, Becker C, de Wilde B, Vandesompele J, Böhm D, Ansén S, Gabler F, Wilkening I et al. (2012)
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer
Nat Genet, 44 (10), 1104-10
DOI 10.1038/ng.2396, PubMed 22941188

Rud AK, Lund-Iversen M, Berge G, Brustugun OT, Solberg SK, Mælandsmo GM, Boye K (2012)
Expression of S100A4, ephrin-A1 and osteopontin in non-small cell lung cancer
BMC Cancer, 12, 333
DOI 10.1186/1471-2407-12-333, PubMed 22853000

Sagerup CM, Småstuen M, Johannesen TB, Helland A, Brustugun OT (2012)
Increasing age and carcinoma not otherwise specified: a 20-year population study of 40,118 lung cancer patients
J Thorac Oncol, 7 (1), 57-63
DOI 10.1097/JTO.0b013e3182307f7e, PubMed 21900838

Waldeland E, Brustugun OT, Ramberg C, Helland Å (2012)
[Stereotactic irradiation in spinal metastases]
Tidsskr Nor Laegeforen, 132 (22), 2478-9
DOI 10.4045/tidsskr.12.1108, PubMed 23338027

Waldeland E, Ramberg C, Arnesen MR, Helland A, Brustugun OT, Malinen E (2012)
Dosimetric impact of a frame-based strategy in stereotactic radiotherapy of lung tumors
Acta Oncol, 51 (5), 603-9
DOI 10.3109/0284186X.2012.658115, PubMed 22304490

Publications 2011

Berg A, Brustugun OT, Lund-Iversen M, Helland Å (2011)
Palmar bullous blistering induced by erlotinib
J Thorac Oncol, 6 (5), 954
DOI 10.1097/JTO.0b013e318211136b, PubMed 21623268

Hammerman PS, Sos ML, Ramos AH, Xu C, Dutt A, Zhou W, Brace LE, Woods BA, Lin W, Zhang J, Deng X, Lim SM, Heynck S, Peifer M, Simard JR, Lawrence MS, Onofrio RC, Salvesen HB, Seidel D, Zander T, Heuckmann JM, Soltermann A, Moch H, Koker M, Leenders F et al. (2011)
Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer
Cancer Discov, 1 (1), 78-89
DOI 10.1158/2159-8274.CD-11-0005, PubMed 22328973

Helland Å, Skaug HM, Kleinberg L, Iversen ML, Rud AK, Fleischer T, Sagerup C, Solberg S, Jørgensen L, Ariansen S, Brustugun OT (2011)
EGFR gene alterations in a Norwegian cohort of lung cancer patients selected for surgery
J Thorac Oncol, 6 (5), 947-50
DOI 10.1097/JTO.0b013e31820db209, PubMed 21623266

Knudtsen IS, Rødal J, Brustugun OT, Helland Å, Skretting A, Malinen E (2011)
Dynamic respiratory gated (18)FDG-PET of lung tumors - a feasibility study
Acta Oncol, 50 (6), 889-96
DOI 10.3109/0284186X.2011.583266, PubMed 21767189

Sagerup CM, Småstuen M, Johannesen TB, Helland Å, Brustugun OT (2011)
Sex-specific trends in lung cancer incidence and survival: a population study of 40,118 cases
Thorax, 66 (4), 301-7
DOI 10.1136/thx.2010.151621, PubMed 21199818

Turzer M, Brustugun OT, Waldeland E, Helland A (2011)
Stereotactic body radiation therapy is effective and safe in patients with early-stage non-small cell lung cancer with low performance status and severe comorbidity
Case Rep Oncol, 4 (1), 25-34
DOI 10.1159/000324113, PubMed 21526003

Publications 2010

Courter D, Cao H, Kwok S, Kong C, Banh A, Kuo P, Bouley DM, Vice C, Brustugun OT, Denko NC, Koong AC, Giaccia A, Le QT (2010)
The RGD domain of human osteopontin promotes tumor growth and metastasis through activation of survival pathways
PLoS One, 5 (3), e9633
DOI 10.1371/journal.pone.0009633, PubMed 20224789

Turzer M, Brustugun OT, Helland A (2010)
Excessive Soft Tissue Reaction after Stereotactic Body Radiation Therapy in a Woman with Four Different Cancer Diagnoses
Case Rep Oncol, 3 (2), 195-201
DOI 10.1159/000317104, PubMed 20740196

Weiss J, Sos ML, Seidel D, Peifer M, Zander T, Heuckmann JM, Ullrich RT, Menon R, Maier S, Soltermann A, Moch H, Wagener P, Fischer F, Heynck S, Koker M, Schöttle J, Leenders F, Gabler F, Dabow I, Querings S, Heukamp LC, Balke-Want H, Ansén S, Rauh D, Baessmann I et al. (2010)
Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer
Sci Transl Med, 2 (62), 62ra93
DOI 10.1126/scitranslmed.3001451, PubMed 21160078

Publications 2009

Helland A, Brustugun OT (2009)
[Lung cancer in smokers and never-smokers]
Tidsskr Nor Laegeforen, 129 (18), 1859-62
DOI 10.4045/tidsskr.08.0652, PubMed 19844277

Sagerup CM, Brustugun OT, Jørgensen L (2009)
[A 67-year old man with right arm paresthesias]
Tidsskr Nor Laegeforen, 129 (24), 2613-5
DOI 10.4045/tidsskr.09.0319, PubMed 20029558

Publications 2008

Fredriksson S, Horecka J, Brustugun OT, Schlingemann J, Koong AC, Tibshirani R, Davis RW (2008)
Multiplexed proximity ligation assays to profile putative plasma biomarkers relevant to pancreatic and ovarian cancer
Clin Chem, 54 (3), 582-9
DOI 10.1373/clinchem.2007.093195, PubMed 18171715

Lyng H, Lando M, Brøvig RS, Svendsrud DH, Johansen M, Galteland E, Brustugun OT, Meza-Zepeda LA, Myklebost O, Kristensen GB, Hovig E, Stokke T (2008)
GeneCount: genome-wide calculation of absolute tumor DNA copy numbers from array comparative genomic hybridization data
Genome Biol, 9 (5), R86
DOI 10.1186/gb-2008-9-5-r86, PubMed 18500990

Publications 2005

Brustugun OT, Reed W, Poulsen JP, Bruland OS (2005)
Primary osteosarcoma of the breast
Acta Oncol, 44 (7), 767-70
DOI 10.1080/02841860500254897, PubMed 16227171

Publications 2004

Lyng H, Beigi M, Svendsrud DH, Brustugun OT, Stokke T, Kristensen GB, Sundfør K, Skjønsberg A, De Angelis PM (2004)
Intratumor chromosomal heterogeneity in advanced carcinomas of the uterine cervix
Int J Cancer, 111 (3), 358-66
DOI 10.1002/ijc.20258, PubMed 15221962

Publications 2003

Brustugun OT, Nome O, Bruland S ØS, Ottestad L, Lilleby W (2003)
[Breast cancer patients' assessment of waiting time before radiotherapy]
Tidsskr Nor Laegeforen, 123 (12), 1685-6
PubMed 12821991

Tronstad KJ, Gjertsen BT, Krakstad C, Berge K, Brustugun OT, Døskeland SO, Berge RK (2003)
Mitochondrial-targeted fatty acid analog induces apoptosis with selective loss of mitochondrial glutathione in promyelocytic leukemia cells
Chem Biol, 10 (7), 609-18
DOI 10.1016/s1074-5521(03)00142-x, PubMed 12890534

Publications 2001

Fladmark KE, Brustugun OT, Mellgren G, Krakstad C, Boe R, Vintermyr OK, Schulman H, Doskeland SO (2001)
Ca2+/calmodulin-dependent protein kinase II is required for microcystin-induced apoptosis
J Biol Chem, 277 (4), 2804-11
DOI 10.1074/jbc.M109049200, PubMed 11713251

Publications 2000

Schwede F, Brustugun OT, Zorn-Kruppa M, Døskeland SO, Jastorff B (2000)
Membrane-permeant, bioactivatable analogues of cGMP as inducers of cell death in IPC-81 leukemia cells
Bioorg Med Chem Lett, 10 (6), 571-3
DOI 10.1016/s0960-894x(00)00050-0, PubMed 10741556

Publications 1999

Fladmark KE, Brustugun OT, Hovland R, Boe R, Gjertsen BT, Zhivotovsky B, Døskeland SO (1999)
Ultrarapid caspase-3 dependent apoptosis induction by serine/threonine phosphatase inhibitors
Cell Death Differ, 6 (11), 1099-108
DOI 10.1038/sj.cdd.4400590, PubMed 10578179

Publications 1998

Brustugun OT (1998)
Apoptosis: role of protein phosphorylation and cytochrome c
Department of Anatomy and Cell Biology, University of Bergen, Bergen, 1 b. (flere pag.)
BIBSYS 99060103x, ISBN 82-91424-12-8

Brustugun OT, Fladmark KE, Doskeland SO, Orrenius S, Zhivotovsky B (1998)
Apoptosis induced by microinjection of cytochrome c is caspase-dependent and is inhibited by Bcl-2
Cell Death Differ, 5 (8), 660-8
DOI 10.1038/sj.cdd.4400399, PubMed 10200521

Zhivotovsky B, Orrenius S, Brustugun OT, Døskeland SO (1998)
Injected cytochrome c induces apoptosis
Nature, 391 (6666), 449-50
DOI 10.1038/35060, PubMed 9461210

Publications 1995

Bruserud O, Tore Gjertsen B, Brustugun OT, Bassøe CF, Nesthus I, Espen Akselsen P, Bühring HJ, Pawelec G (1995)
Effects of interleukin 10 on blast cells derived from patients with acute myelogenous leukemia
Leukemia, 9 (11), 1910-20
PubMed 7475283

Brustugun OT, Mellgren G, Gjertsen BT, Bjerkvig R, Døskeland SO (1995)
Sensitive and rapid detection of beta-galactosidase expression in intact cells by microinjection of fluorescent substrate
Exp Cell Res, 219 (2), 372-8
DOI 10.1006/excr.1995.1241, PubMed 7641787

Vintermyr OK, Bøe R, Brustugun OT, Maronde E, Aakvaag A, Døskeland SO (1995)
Cyclic adenosine monophosphate (cAMP) analogs 8-Cl- and 8-NH2-cAMP induce cell death independently of cAMP kinase-mediated inhibition of the G1/S transition in mammary carcinoma cells (MCF-7)
Endocrinology, 136 (6), 2513-20
DOI 10.1210/endo.136.6.7750473, PubMed 7750473